# M-tron Industries, Inc.: financial statements, quarterly

MPTI · NYSE · CIK 1902314 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mpti.md) · [Financials](/companies/mpti/financials.md) · [Filings](/companies/mpti/filings.md) · [Insiders](/companies/mpti/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mpti/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [10.9](/filings/0001437749-25-009645.md) | [10.8](/filings/0001437749-25-009645.md) | [11.2](/filings/0001437749-26-009844.md) | [11.8](/filings/0001437749-26-009844.md) | [13.2](/filings/0001437749-26-009844.md) | [12.8](/filings/0001437749-26-009844.md) | [12.7](/filings/0001437749-26-016784.md) | [13.3](/filings/0001437749-26-027371.md) | [14.2](/filings/0001437749-26-009844.md) | [14.2](/filings/0001437749-26-009844.md) | [14.7](/filings/0001437749-26-016784.md) | [15.1](/filings/0001437749-26-027371.md) |
| Research and development | $m | [0.6](/filings/0001437749-24-034901.md) | [0.6 d](/filings/0001437749-25-009645.md) | [0.6](/filings/0001437749-25-016515.md) | [0.7](/filings/0001437749-25-026272.md) | [0.7](/filings/0001437749-25-034501.md) | [0.8 d](/filings/0001437749-26-009844.md) | [0.7](/filings/0001437749-26-016784.md) | [0.8](/filings/0001437749-26-027371.md) | [0.8](/filings/0001437749-25-034501.md) | [0.9 d](/filings/0001437749-26-009844.md) | [0.8](/filings/0001437749-26-016784.md) | [1.1](/filings/0001437749-26-027371.md) |
| Operating income | $m | [2.0](/filings/0001437749-25-009645.md) | [(0.1)](/filings/0001437749-25-009645.md) | [1.8](/filings/0001437749-26-009844.md) | [2.1](/filings/0001437749-26-009844.md) | [2.9](/filings/0001437749-26-009844.md) | [2.6](/filings/0001437749-26-009844.md) | [2.0](/filings/0001437749-26-016784.md) | [1.8](/filings/0001437749-26-027371.md) | [2.6](/filings/0001437749-26-009844.md) | [3.9](/filings/0001437749-26-009844.md) | [2.6](/filings/0001437749-26-016784.md) | [1.7](/filings/0001437749-26-027371.md) |
| Income tax | $m | [0.5](/filings/0001437749-25-009645.md) | [(0.0)](/filings/0001437749-25-009645.md) | [0.4](/filings/0001437749-26-009844.md) | [0.4](/filings/0001437749-26-009844.md) | [0.7](/filings/0001437749-26-009844.md) | [0.6](/filings/0001437749-26-009844.md) | [0.5](/filings/0001437749-26-016784.md) | [0.4](/filings/0001437749-26-027371.md) | [0.9](/filings/0001437749-26-009844.md) | [0.7](/filings/0001437749-26-009844.md) | [0.5](/filings/0001437749-26-016784.md) | [0.6](/filings/0001437749-26-027371.md) |
| Net income | $m | [1.6](/filings/0001437749-25-009645.md) | [0.1](/filings/0001437749-25-009645.md) | [1.5](/filings/0001437749-26-009844.md) | [1.7](/filings/0001437749-26-009844.md) | [2.3](/filings/0001437749-26-009844.md) | [2.1](/filings/0001437749-26-009844.md) | [1.6](/filings/0001437749-26-016784.md) | [1.6](/filings/0001437749-26-027371.md) | [1.8](/filings/0001437749-26-009844.md) | [3.4](/filings/0001437749-26-009844.md) | [2.4](/filings/0001437749-26-016784.md) | [1.9](/filings/0001437749-26-027371.md) |
| Diluted EPS | $ per share | [0.57](/filings/0001437749-25-009645.md) | [0.03](/filings/0001437749-25-009645.md) | [0.53](/filings/0001437749-26-009844.md) | [0.63](/filings/0001437749-26-009844.md) | [0.81](/filings/0001437749-26-009844.md) | [0.73](/filings/0001437749-26-009844.md) | [0.56](/filings/0001437749-26-016784.md) | [0.53](/filings/0001437749-26-027371.md) | [0.63](/filings/0001437749-26-009844.md) | [0.99](/filings/0001437749-26-009844.md) | [0.67](/filings/0001437749-26-016784.md) | [0.43](/filings/0001437749-26-027371.md) |
| Basic EPS | $ per share | [0.59](/filings/0001437749-25-009645.md) | [0.03](/filings/0001437749-25-009645.md) | [0.55](/filings/0001437749-26-009844.md) | [0.64](/filings/0001437749-26-009844.md) | [0.82](/filings/0001437749-26-009844.md) | [0.76](/filings/0001437749-26-009844.md) | [0.57](/filings/0001437749-26-016784.md) | [0.55](/filings/0001437749-26-027371.md) | [0.64](/filings/0001437749-26-009844.md) | [1.16](/filings/0001437749-26-009844.md) | [0.68](/filings/0001437749-26-016784.md) | [0.46](/filings/0001437749-26-027371.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.6](/filings/0001437749-23-031260.md) | [3.9](/filings/0001437749-25-009645.md) | [5.4](/filings/0001437749-24-016652.md) | [6.5](/filings/0001437749-24-026572.md) | [8.5](/filings/0001437749-24-034901.md) | [12.6](/filings/0001437749-26-009844.md) | [13.7](/filings/0001437749-25-016515.md) | [15.5](/filings/0001437749-25-026272.md) | [18.3](/filings/0001437749-25-034501.md) | [20.9](/filings/0001437749-26-027371.md) | [52.0](/filings/0001437749-26-016784.md) | [96.2](/filings/0001437749-26-027371.md) |
| Current assets | $m | [17.0](/filings/0001437749-23-031260.md) | [18.2](/filings/0001437749-25-009645.md) | [20.7](/filings/0001437749-24-016652.md) | [21.7](/filings/0001437749-24-026572.md) | [24.7](/filings/0001437749-24-034901.md) | [29.8](/filings/0001437749-26-009844.md) | [30.4](/filings/0001437749-25-016515.md) | [31.8](/filings/0001437749-25-026272.md) | [34.9](/filings/0001437749-25-034501.md) | [61.2](/filings/0001437749-26-027371.md) | [71.9](/filings/0001437749-26-016784.md) | [118](/filings/0001437749-26-027371.md) |
| Total assets | $m | [21.8](/filings/0001437749-23-031260.md) | [24.3](/filings/0001437749-25-009645.md) | [26.8](/filings/0001437749-24-016652.md) | [28.4](/filings/0001437749-24-026572.md) | [31.5](/filings/0001437749-24-034901.md) | [36.6](/filings/0001437749-26-009844.md) | [37.8](/filings/0001437749-25-016515.md) | [39.7](/filings/0001437749-25-026272.md) | [42.2](/filings/0001437749-25-034501.md) | [68.4](/filings/0001437749-26-027371.md) | [79.3](/filings/0001437749-26-016784.md) | [126](/filings/0001437749-26-027371.md) |
| Current liabilities | $m | [4.0](/filings/0001437749-23-031260.md) | [4.4](/filings/0001437749-25-009645.md) | [5.1](/filings/0001437749-24-016652.md) | [4.7](/filings/0001437749-24-026572.md) | [5.3](/filings/0001437749-24-034901.md) | [5.2](/filings/0001437749-26-009844.md) | [4.6](/filings/0001437749-25-016515.md) | [4.7](/filings/0001437749-25-026272.md) | [5.1](/filings/0001437749-25-034501.md) | [4.9](/filings/0001437749-26-027371.md) | [6.1](/filings/0001437749-26-016784.md) | [7.1](/filings/0001437749-26-027371.md) |
| Total liabilities | $m | [4.0](/filings/0001437749-23-031260.md) | [4.4](/filings/0001437749-25-009645.md) | [5.1](/filings/0001437749-24-016652.md) | [4.7](/filings/0001437749-24-026572.md) | [5.3](/filings/0001437749-24-034901.md) | [5.3](/filings/0001437749-26-009844.md) | [4.6](/filings/0001437749-25-016515.md) | [4.9](/filings/0001437749-25-026272.md) | [5.2](/filings/0001437749-25-034501.md) | [5.2](/filings/0001437749-26-027371.md) | [6.2](/filings/0001437749-26-016784.md) | [7.2](/filings/0001437749-26-027371.md) |
| Shareholders' equity | $m | [17.8](/filings/0001437749-24-034901.md) | [19.9](/filings/0001437749-26-009844.md) | [21.7](/filings/0001437749-25-026272.md) | [23.7](/filings/0001437749-25-034501.md) | [26.2](/filings/0001437749-25-034501.md) | [31.3](/filings/0001437749-26-027371.md) | [33.2](/filings/0001437749-26-027371.md) | [34.8](/filings/0001437749-26-027371.md) | [37.0](/filings/0001437749-25-034501.md) | [63.2](/filings/0001437749-26-027371.md) | [73.1](/filings/0001437749-26-027371.md) | [119](/filings/0001437749-26-027371.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [1,494 d](/filings/0001437749-24-034901.md) | [2,132 d](/filings/0001437749-25-009645.md) | [1,496](/filings/0001437749-25-016515.md) | [1,960 d](/filings/0001437749-25-026272.md) | [2,251 d](/filings/0001437749-25-034501.md) | [1,814 d](/filings/0001437749-26-009844.md) | [1,607](/filings/0001437749-26-016784.md) | [2,855 d](/filings/0001437749-26-027371.md) | [3,517 d](/filings/0001437749-25-034501.md) | [2,680 d](/filings/0001437749-26-009844.md) | [2,118](/filings/0001437749-26-016784.md) | [3,704 d](/filings/0001437749-26-027371.md) |
| Capital expenditure | $k | [263 d](/filings/0001437749-24-034901.md) | [716 d](/filings/0001437749-25-009645.md) | [122](/filings/0001437749-25-016515.md) | [873 d](/filings/0001437749-25-026272.md) | [478 d](/filings/0001437749-25-034501.md) | [425 d](/filings/0001437749-26-009844.md) | [586](/filings/0001437749-26-016784.md) | [812 d](/filings/0001437749-26-027371.md) | [807 d](/filings/0001437749-25-034501.md) | [346 d](/filings/0001437749-26-009844.md) | [452](/filings/0001437749-26-016784.md) | [937 d](/filings/0001437749-26-027371.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [2,760](/filings/0001437749-25-009645.md) | [2,774](/filings/0001437749-25-009645.md) | [2,785](/filings/0001437749-26-009844.md) | [2,780](/filings/0001437749-26-009844.md) | [2,801](/filings/0001437749-26-009844.md) | [2,925](/filings/0001437749-26-009844.md) | [2,906](/filings/0001437749-26-016784.md) | [2,935](/filings/0001437749-26-027371.md) | [2,916](/filings/0001437749-26-009844.md) | [3,445](/filings/0001437749-26-009844.md) | [3,572](/filings/0001437749-26-016784.md) | [4,339](/filings/0001437749-26-027371.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,346,476 at 2026-07-31, from the cover of the [10-Q filed 2026-08-12](/filings/0001437749-26-027371.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.